A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Launched by TSCAN THERAPEUTICS, INC. · Mar 31, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on collecting samples from patients with specific types of advanced solid tumors, such as head and neck cancer, cervical cancer, non-small cell lung cancer, melanoma, and ovarian cancer. The goal is to analyze these samples to help determine if patients have certain markers that could make them eligible for future TScan clinical treatment studies. Essentially, researchers are looking to understand how specific proteins related to cancer are presented in patients’ tumors, which could help in developing personalized cell therapies.

To participate, you need to be at least 18 years old and willing to provide written consent. You should have a confirmed diagnosis of one of the targeted cancers and be able to provide a saliva sample and a tumor sample (either a recent biopsy or an existing tumor block). Participants will be helping advance research that may lead to new treatment options, and they can expect to contribute valuable information that could benefit others with similar conditions in the future. It’s important to note that if you are currently receiving treatments aimed at curing your cancer, you may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willing and able to provide written informed consent.
• • Male or female aged ≥18 years at the time of signing the informed consent.
• * Have one of the following histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor for which the Sponsor has an associated clinical study:
• • Head and neck cancer
• • Cervical cancer
• • Non-small cell lung cancer
• • HPV positive anogenital cancers
• • Sarcoma
• • Other cancers with a reasonable likelihood of expressing 1 or more antigens included in a TScan clinical trial, following approval by the TScan Medical Monitor or their delegate.
• • Willing to provide a buccal swab for HLA testing
• • Willing to provide a saliva sample to use as a normal control for the LOH assay
• • Have access to an adequate FFPE tumor block that is \<8 months old or is willing to provide a fresh core-needle biopsy from a location deemed safe by the treating medical team.
• Exclusion Criteria:
• • • Participants undergoing anticancer therapy with curative intent such as tumor surgical resection with or without neoadjuvant/adjuvant therapy, or definitive chemoradiation, unless they have locoregionally advanced disease and are expected to have a high risk of relapse after their curative intent therapy as determined by the treating investigator.